Impact of COVID-19 on Lung Cancer Patients

NCT04538456 | Completed

• 1 other identifier: CFTSp189
• Study Type: observational
• Target: 296
• Locations: 1 country
• Sites: 1

Brief Summary

During the COVID-19 pandemic, people's lives have changed dramatically. People with lung cancer who are shielding may have been particularly affected as they may be unable to carry out many of their normal daily activities, such as grocery shopping and exercise, and are unable to interact with friends and family. People with lung cancer will also have experienced some changes to the clinical services available to them at The Christie. Using a questionnaire and interviews, the investigators want to understand patient experiences of the changes in their daily lives and the changes to their clinical care. This will help us to see if people with lung cancer need any additional support services or if there are any changes the investigators can make to clinical services to improve patient experiences. Eligible patients will be any lung cancer patients receiving current treatment or in active follow up.

Conditions

Lung Cancer; PROM; Covid19; Psychological

Outcome Measures

Primary Outcomes (2)

• Physical and Social impact

  Physical and social impact will be captured by the EuroQual-5D quality of life and questions regarding patient's diagnosis and treatment pathway including a list of symptoms based on the Common Terminology Criteria for Adverse Events.

  baseline

• Psychological impact

  Emotional impact will be assessed using the Hospital Anxiety Depression Scale. Scores range from 0-21 for each of the two subscales (anxiety and depression), with higher scores indicating greater anxiety and depression.

  baseline

Secondary Outcomes (1)

• prevalence and impact of frailty

  baseline

Study Arms (2)

used electronic Patient Reported Outcome Measures

Lung cancer patients who have used the electronic Patient Reported Outcome Measures system before and after COVID-19 lock down or new patients who have completed their first electronic Patient Reported Outcome Measures after COVID-19 lock down.

Other: questionnaire and optional interview

never used electronic Patient Reported Outcome Measures

Lung cancer patients who have never completed electronic Patient Reported Outcome Measures.

Other: questionnaire and optional interview

Interventions

questionnaire and optional interview OTHER

Participants will be sent an online or paper questionnaire. If participants have expressed an interest in taking part in an interview, they may be contacted by a member of the research team. The interviews will be conducted over the phone at time suitable for the participant. There will be no study specific hospital visits.

never used electronic Patient Reported Outcome Measures; used electronic Patient Reported Outcome Measures

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Additionally, participants will need to meet the criteria to be selected for one of the two cohorts of patients: 1. Lung cancer patients voluntarily using the ePROMs platform with at least 1 assessment completed in the 6 months prior to 23 March 2020 (COVID-19 lockdown date) and 1 assessment after this date or new patients who have completed their first electronic Patient Reported Outcome Measures after 23 March 2020 2. Lung cancer patients who have never complete electronic Patient Reported Outcome Measures data.

You may qualify if:

• non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC)
• patients in active treatment or in clinical follow-up

You may not qualify if:

• Lung cancer patients who do not speak or understand English will not be eligible to take part in the study
• Patients under the age of 18 will be eligible for the study

Sponsors & Collaborators

• The Christie NHS Foundation Trust: lead

Study Sites (1)

The Christie NHS Foundation

Manchester, m20 4bx, United Kingdom

Location

Related Links

• Link to third publication
• Link to second publication
• Link to HRA summary of results

MeSH Terms

Conditions

Lung Neoplasms; COVID-19

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 1, 2020
• First Posted: September 4, 2020
• Study Start: October 15, 2020
• Primary Completion: April 16, 2022
• Study Completion: April 16, 2022
• Last Updated: April 24, 2024

Record last verified: 2024-04

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)